Stocks Health care SABS
NASDAQ · Health careSAB Biotherapeutics, Inc. (SABS)
It posted a net loss of $80.5M. In fiscal 2025 capital spending exceeded operating cash flow by $45.7M. At September 30, 2026 it held $14.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about SAB Biotherapeutics, Inc.
- Net worth
- SAB Biotherapeutics, Inc. has a market value (market cap) of $279.3M at the latest share price, and shareholders' equity of $210.9M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $44.8M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- SAB Biotherapeutics, Inc.'s next report is expected around March 8, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What SAB Biotherapeutics, Inc. does
SAB Biotherapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker SABS.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $0 | $13.3M | -$0.79 | -$45.7M |
| 2024 | $1.3M | -$34.1M | -$3.68 | -$34.6M |
| 2023 | $2.2M | -$42.2M | -$7.64 | -$25.3M |
| 2022 | $23.9M | -$18.7M | -$4.31 | -$25.6M |
| 2021 | $60.9M | -$17.1M | -$0.63 | -$9M |
| 2020 | $55.2M | $20.1M | $0.74 | -$2.7M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What SAB Biotherapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026
- October 22, 2026Delisting notice 25-NSE
- October 13, 2026Other event 8-K
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 12, 2026Passive stake (5% or more) SCHEDULE 13G
Insider trades
What the people running SAB Biotherapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 1 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 17, 2026 | Kropotova AlexandraCHIEF MEDICAL OFFICER | Shares withheld for tax | 473 | - |
| June 25, 2026 | Kropotova AlexandraCHIEF MEDICAL OFFICER | Shares withheld for tax | 988 | - |
| March 24, 2026 | Kropotova AlexandraCHIEF MEDICAL OFFICER | Shares withheld for tax | 988 | - |
| December 11, 2025 | Kropotova AlexandraCHIEF MEDICAL OFFICER | Shares withheld for tax | 988 | - |
Who owns SABS
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Vivo Opportunity Fund Holdings, L.P.13G, passive with 3 related filers | 9.99% | August 14, 2026 |
| Commodore Capital LP13G, passive with 3 related filers | 9.9% | August 14, 2026 |
| RA Capital Management, L.P.13D, may seek influence with 3 related filers | 9.9% | August 10, 2026 |
| Balyasny Asset Management L.P.13G, passive with 4 related filers | 9.45% | August 14, 2026 |
| Bvf Partners L P13G, passive with 9 related filers | 9.1% | February 17, 2026 |
| Caligan Partners LP13G, passive with 1 related filers | 8.8% | August 14, 2026 |
| Adage Capital Management, L.P.13G, passive with 2 related filers | 8.38% | August 12, 2026 |
| Perceptive Advisors LLC13G, passive with 2 related filers | 7.3% | August 14, 2026 |
| Woodline Partners LP13G, passive | 6.8% | August 14, 2026 |
| Millennium Management LLC13G, passive with 2 related filers | 5.1% | May 1, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 87 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Caligan Partners LP | 7,967,207 | 0 |
| Vivo Capital, LLC | 7,299,909 | -4,120,091 |
| Perceptive Advisors LLC | 6,627,501 | +195,758 |
| Adage Capital Partners GP, L.L.C. | 6,405,553 | +3,000,000 |
| RA Capital Management, L.P. | 4,401,500 | 0 |
| Balyasny Asset Management L.P. | 3,760,439 | 0 |
| BlackRock, Inc. | 3,066,016 | +2,764,690 |
| Vanguard Capital Management LLC | 2,972,929 | +479,192 |
| Commodore Capital LP | 2,870,000 | -1,531,500 |
| Millennium Management LLC | 2,749,087 | -283,610 |
| Spruce Street Capital LP | 2,198,502 | 0 |
| Sessa Capital IM, L.P. | 2,198,457 | 0 |
| Affinity Asset Advisors, LLC | 1,525,000 | +950,000 |
| Boothbay Fund Management, LLC | 1,481,660 | 0 |
| Geode Capital Management, LLC | 1,277,185 | +975,149 |
| Woodline Partners LP | 1,180,355 | -1,671,436 |
| Ensign Peak Advisors, Inc | 1,172,641 | -202,969 |
| Propel Bio Management, LLC | 1,076,578 | +63,788 |
| Soleus Capital Management, L.P. | 900,000 | -150,000 |
| Seven Fleet Capital Management LP | 736,077 | +636,077 |
Insiders
1 insiders reported holding 41,853 shares in total, about $128.5K at the last price.
| Holder | Shares |
|---|---|
| Kropotova AlexandraCHIEF MEDICAL OFFICER | 41,853 |
Questions about SABS
What does SAB Biotherapeutics, Inc. do?
SAB Biotherapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as SABS. Its shares trade on NASDAQ under the ticker SABS.
What is SAB Biotherapeutics, Inc.'s net worth?
SAB Biotherapeutics, Inc. has a market value (market cap) of $279.3M at the latest share price, and shareholders' equity of $210.9M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is SAB Biotherapeutics, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $80.5M.
When did SAB Biotherapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026.
When is SAB Biotherapeutics, Inc.'s next earnings report?
SAB Biotherapeutics, Inc.'s next report is expected around March 8, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare SABS with
Follow SABS
Get an email when SAB Biotherapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values SAB Biotherapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.